Skip to content

Inhaled Budesonide in Transient Tachypnea of the Newborn

Inhaled Budesonide in Transient Tachypnea of the Newborn: A Randomized, Placebo-controlled Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04758078
Enrollment
50
Registered
2021-02-17
Start date
2021-02-15
Completion date
2021-08-31
Last updated
2021-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Distress

Brief summary

Background: Transient tachypnea of the newborn (TTN) caused by lung edema resulting from delayed absorption of fetal alveolar lung fluid and is a common cause of admission of late preterm and full-term infants to neonatal intensive care units. Infant born by C-section and those with perinatal asphyxia, umbilical cord prolapse or certain maternal condition (asthma, diabetes, or analgesia) are more prone to develop TTN. Conventional treatment involves appropriate oxygen administration and continuous positive airway pressure in some cases. Hastening the clearance of lung liquid should shorten the duration of the symptoms and reduce complications. Objectives: This study aims to determine the effectiveness of inhaled budesonide in the treatment of this disorder through determining whether it reduces the duration of oxygen therapy and respiratory symptoms and shortens hospital stay in term infants with transient tachypnea of the newborn

Interventions

Budesonide 2 mL = 1000 microgram will be given within 6 hours of birth and the second dose will be given after 12 hours

OTHERPlacebo

Nebulized 0.9% saline will be given four times per day

Sponsors

Makassed General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
34 Weeks to No maximum
Healthy volunteers
No

Inclusion criteria

* Late preterm and term infants (post-menstrual age ≥ 34 weeks) delivered by Cesarean section or vaginal delivery * Diagnosis of transient tachypnea of the newborn * The need for Continuous positive airway pressure (CPAP) \>6 hours to obtain the oxygen saturation \>92%

Exclusion criteria

* Meconium aspiration syndrome; * Respiratory distress syndrome * Congenital heart Disease * Non respiratory disorders causing tachypnea (polycythemia or hypoglycemia) resolving with treatment of the disorder * Pneumonia by chest x-ray * Suspected sepsis/bacteremia * Prenatal steroids

Design outcomes

Primary

MeasureTime frameDescription
Assessment of respiratory distresswithin 48 hoursTransient tachypnea of the newborn clinical score

Secondary

MeasureTime frameDescription
Assessment of time to spontaneous breathingwith 48 hoursTime to spontaneous unsupported breathing of room air (in hours)

Countries

Lebanon

Contacts

Primary ContactSirin Mneimneh, MD
sirin.mneimneh@hotmail.com+9611636000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026